The FDA finalized two rules to make certain unapproved medicines more accessible to critically ill patients who failed to respond to other treatments. The regulations guide patients in getting drugs outside clinical trials and give smaller firms a chance to participate in expanded-access programs by allowing companies and researchers to charge patients for the treatments.

Related Summaries